These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25688115)

  • 21. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
    Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
    PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Independent Prognostic Value of Asphericity of
    Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
    Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
    Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
    Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
    Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic importance of
    Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
    Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS
    Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
    Lee P; Bazan JG; Lavori PW; Weerasuriya DK; Quon A; Le QT; Wakelee HA; Graves EE; Loo BW
    Clin Lung Cancer; 2012 Jan; 13(1):52-58. PubMed ID: 21703935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
    Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
    J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.